Bird & Be's Latest Funding Round
Toronto-based Bird & Be, a company known for clinically-backed, doctor-approved prenatal vitamins and at-home tests for both females and males, has successfully raised $18.3 million in a Series A funding round. This round was co-led by the Business Development Bank of Canada (BDC) and Thrive Fund. Additional investors include BFG Partners, BAM Ventures, Founder Collective, Rejuvenation Ventures, and HSR Ventures.
Company Overview
Founded in 2019, Bird & Be addresses the rising global infertility rates by offering a subscription service for fertility and wellness supplements, as well as test kits. These products are designed to support individuals and couples on their journey to parenthood, providing reliable and convenient solutions.
Leadership Team
The company was co-founded by Samantha Diamond, who serves as the CEO, and Shannon Gallagher, the Chief Growth Officer. Both founders have personal experience with reproductive health challenges, which drives their commitment to the company's mission.
Use of Funds
The newly acquired funds are expected to be used for expanding Bird & Be's product offerings and enhancing their customer reach. With the fertility tech market rapidly growing in North America, the company plans to leverage this investment to scale its operations and meet increasing demand.
Market Context
Bird & Be operates in a market where approximately one in six people globally experience infertility issues, according to the World Health Organization. The company's offerings are particularly relevant as studies indicate a significant decline in male fertility over the past 40 years, highlighting the need for comprehensive reproductive health solutions for both sexes.
Conclusion
With this latest funding round, Bird & Be is well-positioned to continue its growth and support more individuals in addressing fertility challenges. The company's focus on both male and female reproductive health sets it apart in the fertility support sector.